Under construction – not a live service
Sign in
Taking people in ChinaNo phase

CPAP treatment after atrial fibrillation ablation in people with obstructive sleep apnea

Tests CPAP in people with sleep apnea after atrial fibrillation ablation.

Plain-language title generated from the registry record
Registry title: Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation

Key facts

Where
Beijing, Changchun, Changsha, Dalian, Dongying, Fuzhou, Harbin, Kunming, Langfang, Linyi, Nanjing, Nanning, Ningbo, Shangqiu, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xingtai, Zhangzhou, and Zhengzhou, ChinaSee the 30 sites

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with persistent atrial fibrillation who had their first catheter ablation and also have obstructive sleep apnea. It tests whether using a CPAP device afterwards helps.

Age
18 to 75 years
Sex
All sexes can join.
Disease stage
Persistent atrial fibrillation, treated with catheter ablation for the first time, plus a diagnosis of obstructive sleep apnea.
Earlier treatment
Must have had a first catheter ablation for atrial fibrillation. Must not have had CPAP, oral appliances, ENT surgery or bariatric surgery for sleep apnea in the 3 months before screening.

Main reasons for not taking part

  • Secondary atrial fibrillation
  • Central sleep apnea, or conditions that need breathing support
  • Left ventricular ejection fraction < 30%
  • Pregnant or breastfeeding women
  • Heart attack, heart procedure or heart surgery within 3 months, or stroke or mini-stroke within 6 months before screening

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Source: NCT07444372, who can take part

Where in China

  • Beijing Anzhen HospitalBeijing, ChinaContact: Jiang Xie, ProfessorTaking people
  • Beijing Chaoyang Hospital, Capital Medical UniversityBeijing, ChinaContact: Zhiling Zhao, ProfessorNot yet recruiting
  • Beijing HospitalBeijing, ChinaContact: Wei Gong, ProfessorNot yet recruiting
  • Beijing Jishuitan HospitalBeijing, ChinaContact: Yang Cheng, ProfessorNot yet recruiting
  • Peking University International HospitalBeijing, ChinaContact: Yanwen Jiang, ProfessorNot yet recruiting
  • The First Hospital of Jilin UniversityChangchun, ChinaContact: Haibo Yuan, ProfessorNot yet recruiting
  • The Second Xiangya Hospital of Central South UniversityChangsha, ChinaContact: Ruoyun Ouyang, ProfessorNot yet recruiting
  • First Affiliated Hospital of Dalian Medical UniversityDalian, ChinaContact: Haiying Tang, ProfessorNot yet recruiting
  • Shengli Oilfield Central HospitalDongying, ChinaContact: Xiangfei Liu, ProfessorNot yet recruiting
  • First Affiliated Hospital of Fujian Medical UniversityFuzhou, ChinaContact: Ningfang Lian, ProfessorNot yet recruiting
  • Fujian Medical University Union HospitalFuzhou, ChinaContact: Xiangqi Chen, ProfessorNot yet recruiting
  • Second Affiliated Hospital of Harbin Medical UniversityHarbin, ChinaContact: Wei Meng, ProfessorNot yet recruiting
  • Yan'an Hospital of Kunming CityKunming, ChinaContact: Xia Jiang, ProfessorNot yet recruiting
  • Langfang People's HospitalLangfang, ChinaContact: Zengming Xue, ProfessorNot yet recruiting
  • Linyi People's HospitalLinyi, ChinaContact: Li Wei, ProfessorNot yet recruiting
  • The First Affiliated Hospital of Nanjing Medical UniversityNanjing, ChinaContact: Ning Ding, ProfessorNot yet recruiting
  • People's Hospital of Guangxi Zhuang Autonomous RegionNanning, ChinaContact: Mingming Zhao, ProfessorNot yet recruiting
  • First Affiliated Hospital of Ningbo UniversityNingbo, ChinaContact: Maoqing Tong, ProfessorNot yet recruiting
  • Shangqiu First People's HospitalShangqiu, ChinaContact: Renshan Niu, ProfessorNot yet recruiting
  • First Affiliated Hospital of China Medical UniversityShenyang, ChinaContact: Wenyang Li, ProfessorNot yet recruiting
  • Shengjing Hospital Of China Medical UniversityShenyang, ChinaContact: Li Xiao, ProfessorNot yet recruiting
  • Shijiazhuang Great Wall Hospital of Integrated Traditional Chinese and Western MedicineShijiazhuang, ChinaContact: Linyi Huang, ProfessorTaking people
  • Second hospital of Shanxi Medical UniversityTaiyuan, ChinaContact: Xiaoling Gao, ProfessorNot yet recruiting
  • Tianjin Chest HospitalTianjin, ChinaContact: Fang Zhao, ProfessorNot yet recruiting
  • Tianjin Medical University Second HospitalTianjin, ChinaContact: Xiaoyun Zhao, ProfessorNot yet recruiting
  • Wuhan Asia General HospitalWuhan, ChinaContact: Ning Man, ProfessorNot yet recruiting
  • Wuhan NO.1 HospitalWuhan, ChinaContact: Zhihua Yu, ProfessorNot yet recruiting
  • The Ninth Hospital of XingtaiXingtai, ChinaContact: Zhanwei Liu, ProfessorTaking people
  • Zhangzhou Hospital of Fujian ProvinceZhangzhou, ChinaContact: Li Lin, ProfessorNot yet recruiting
  • The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, ChinaContact: Gangqiong LiuNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Beijing Anzhen Hospital
Trial code
NCT07444372
Record updated
5 October 2026
Original description
Atrial fibrillation (AF) is one of the most common clinical arrhythmias. Catheter ablation is an effective therapeutic strategy; however, recurrence rates remain substantial, ranging from 20% to 45%. Previous studies have established a strong association between obstructive sleep apnea (OSA) and the risk of AF recurrence following ablation. While continuous positive airway pressure (CPAP) is the standard intervention for OSA, and some observational studies suggest it may reduce post-ablation recurrence in patients with comorbid OSA, small randomized controlled trials have failed to confirm a clear benefit, potentially due to poor adherence.Read full original descriptionShow less

Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation: A Multicenter, Open-label, Randomized Clinical Trial

Atrial fibrillation (AF) is one of the most common clinical arrhythmias. Catheter ablation is an effective therapeutic strategy; however, recurrence rates remain substantial, ranging from 20% to 45%. Previous studies have established a strong association between obstructive sleep apnea (OSA) and the risk of AF recurrence following ablation. While continuous positive airway pressure (CPAP) is the standard intervention for OSA, and some observational studies suggest it may reduce post-ablation recurrence in patients with comorbid OSA, small randomized controlled trials have failed to confirm a clear benefit, potentially due to poor adherence.

This study aims to evaluate the clinical benefit of post-ablation CPAP therapy in AF patients with comorbid OSA.

Participants will:

* Be randomly assigned to either the CPAP group or the usual care group. * If in the CPAP group, use a CPAP device for 12 months. * Wear an ambulatory ECG recorder for a 7-day period at 3, 6, 9, and 12 months after randomization. * Complete follow-up checkups either at the clinic or over the phone at 1, 3, 6, and 12 months after randomization.

Inclusion: Patients must meet all of the following conditions to be eligible for the study:; Age 18-75 years; Patients with persistent AF who received catheter ablation for the first time; Diagnosed with OSA; Able to tolerate CPAP therapy; Capable of understanding and complying with the study protocol; Willing to sign the informed consent form.

Exclusion: History of myocardial infarction, percutaneous coronary intervention, or cardiac surgery within 3 months prior to screening; History of stroke or transient ischemic attack within 6 months prior to screening; Perioperative complications related to the ablation procedure occurring prior to randomization; Inability to discontinue antiarrhythmic drugs (AADs) post-procedure due to other reasons; Treatment-emergent central sleep apnea during CPAP tolerance assessment that cannot be corrected prior to randomization; Receipt of instrumental or surgical treatment for OSA within 3 months prior to screening, including CPAP, oral appliances, ENT surgery, or bariatric surgery; Current participation in other drug or device trials; Comorbid moderate-to-severe mitral stenosis or history of prosthetic valve replacement (mechanical or bioprosthetic); Conditions requiring ventilatory support, including obesity hypoventilation syndrome (defined as BMI > 30kg/m² and awake PaCO₂ > 45mmHg), amyotrophic lateral sclerosis, or chronic obstructive pulmonary disease with > 1 episode of respiratory failure or hypercapnia; Left ventricular ejection fraction < 30%; Use of glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide receptor agonists, or glucagon receptor agonists for weight loss within 3 months prior to screening, or plans to initiate such medications within the next year; Patients meeting any of the following criteria will be excluded from the study:; Secondary AF; Left atrial anteroposterior diameter 60mm (measured via parasternal long-axis view); Pregnant or breastfeeding women; Life expectancy < 1 year; Central sleep apnea.

ClinicalTrials.gov NCT07444372